Compare Sea Limited (SE) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sea Limited vs Tango Therapeutics Inc. — how do they compare? Sea Limited trades at $95.84 (market cap $58.76B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Sea Limited is far larger — about 15.7× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sea Limited for 103 Days and Tango Therapeutics Inc. for 0 Days on average.
| SE | TNGX | |
|---|---|---|
Market Cap | $58.76B | $3.75B |
Volume | 5,236,560 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $165.70 | $32.90 |
52-Week Low | $78.16 | $7.50 |
Typical Hold Time | 103 Days | 0 Days |
Enterprise Value | $53.78B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sea Limited (SE) trades at $95.93, showing minimal daily movement with a 0.05% gain. The stock faces bearish technical signals but maintains strong fundamental growth with revenue increasing from $12.4B in 2022 to $22.9B in 2025. Recent earnings show mixed results with Q4 2025 missing expectations but Q1 and Q2 2026 beating estimates. Analyst sentiment remains overwhelmingly positive with 72.7% buy ratings and a $153.67 consensus price target representing 60% upside potential.
Sea's investment case hinges on continued e-commerce and fintech expansion, though recent insider selling and competitive pressures pose risks. The company's improving profitability trajectory and strong cash flow generation support long-term growth prospects, but investors should monitor execution on Shopee's margin improvement and Garena's gaming segment stability amid market volatility.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
